Genmab — September 2016
-
Vi har USA og så tallene fra Europa som vi ikke kender.
-
Ingen tvivl om de sammenlagt kører over juli.
-
Vi har vel ramt loftet i USA med patienter nu i den nuværende linje. Hertil skal lægges salget fra Europa som først lige er startet.
-
"Verdens bedste drug" kan ikke sælge mere end der patienter til. Det ved markedet da efterhånden.
-
Salget er stigende pga Europa kommer til.
-
Aftensmaden er på bordet . Vi snakkes ved.
-
Kører fortsat fint på amyloidosis-fronten http://www.onclive.com/web-exclusives/daratumumab-produces-dramatic-responses-in-relapsed-light-chain-amyloidosis
-
-
Bulder ved du om amyloidosis er et stort marked?
-
Though primary systemic amyloidosis is very rare disease but it has spread across the world. According to article published by American Society of Nephrology (ASN), it is estimated that around five to twelve people per million per year are affected by primary systemic amyloidosis
-
OK men tak for indsatsen. Måske hører vi fra Solsen senere.
-
5-10 gange færre pts end MM http://ojrd.biomedcentral.com/articles/10.1186/1750-1172-7-54
). Det vigtige er at det er de første målinger uden for MM, og de er lovende!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind